-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
NRX Pharmaceuticals, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q4 2017 to Q2 2024.
- NRX Pharmaceuticals, Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2024 was -$847K, a 60.1% decline year-over-year.
- NRX Pharmaceuticals, Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was -$1.56M, a 35.8% increase year-over-year.
- NRX Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2023 was -$2.31M, a 150% decline from 2022.
- NRX Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2022 was $4.58M, a 79.8% decline from 2021.
- NRX Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2021 was $22.7M.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)